In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment.They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape.This episode is sponsored by Roche.TOGA's SCLC Masterclass will take place 20 March 2026, at Novotel on Collins, MelbourneAn advanced workshop covering evolving standards of care and new therapies in SCLC.Early bird tickets available until 16 Feb 2026 https://thoraciconcology.org.au/events/masterclass-small-cell-lung-cancer/RESOURCES AND LINKS:CREST trial https://pmc.ncbi.nlm.nih.gov/articles/PMC3058352/Caspian Study https://www.sciencedirect.com/science/article/pii/S1525730425001640CHEST RT https://trog.com.au/trials/trog-20-01-chest-rt/DeLLphi-303 https://www.annalsofoncology.org/article/S0923-7534(25)04288-7/fulltextIMforte https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006Japan study PCI vs MRIhttps://pubmed.ncbi.nlm.nih.gov/28343976/TIMESTAMPS:(00:00) Introduction and Acknowledgements(00:36) Overview of Small Cell Lung Cancer(02:03) Current First-Line Treatments(06:59) Radiotherapy in Small Cell Lung Cancer(11:36) New Developments in Maintenance and Second-Line Treatments(15:35) Exciting New Therapies and Future Directions(24:01) Radiotherapy and Immune Engaging Therapies(32:53) Conclusion and Future EventsKEYWORDS: SCLC, ES-SCLC, Small Cell Lung Cancer, Early Stage Small Cell Lung Cancer

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related